Sanofi will build a production site and an R&D facility near Lyon in efforts to make homeland France the center of its global vaccine efforts. The plant in Neuville sur Saône, north of Lyon, France, represents an investment of €490 million ($550 million). It will be modular in its design and dedicated to vaccine production and is being set up to respond to future epidemics. The R&D center in Marcy-l’Etoile, west of Lyon, represents €120 million and will look to…
Emergent Biosolutions has set out to capture a share of the expanding viral vector and gene therapy sector. The US countermeasures developer said it will spend $75 million to add viral vector and gene therapy manufacturing capacity at a facility in Canton, Massachusetts. At present the plant – which was acquired from Sanofi in 2017 – produces drug substance for live viral vaccines, including Emergent’s smallpox jab ACAM2000. Emergent said the investment will establish a multi-suite production operation with 1,000…